Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) | |
US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 11 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 16, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 2027-11-17
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE;ORAL
10
United States
3
European Union
2
China
2
Canada
2
Japan
2
Korea, Republic of
1
Italy
1
Spain
1
Austria
1
Denmark
1
RS
1
Germany
1
Poland
1
Croatia
1
Cyprus
1
Portugal
1
Mexico
1
South Africa
1
Slovenia
1
Hungary
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7662365 | REDHILL | Polymer conjugates of opioid antagonists |
Oct, 2022
(7 months ago) | |
US7786133 | REDHILL | Chemically modified small molecules |
Sep, 2028
(5 years from now) | |
US9012469 | REDHILL | Crystalline naloxol-peg conjugate |
Apr, 2032
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8617530 | REDHILL | Polymer conjugates of opioid antagonists |
Oct, 2022
(7 months ago) | |
US7056500 | REDHILL | Polymer conjugates of opioid antagonists |
Jun, 2024
(1 year, 1 month from now) | |
US8067431 | REDHILL | Chemically modified small molecules |
Dec, 2024
(1 year, 6 months from now) |
Drugs and Companies using NALOXEGOL OXALATE ingredient
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
22
United States
8
European Union
7
Spain
6
Australia
4
Hong Kong
4
Denmark
4
China
4
Canada
4
Japan
4
New Zealand
4
Korea, Republic of
4
Cyprus
4
Portugal
4
Slovenia
3
EA
2
RS
2
Poland
2
Croatia
2
Israel
2
Mexico
2
Lithuania
2
Hungary
1
Uruguay
1
Malaysia
1
Brazil
1
Ukraine
1
Singapore
1
Argentina
1
ME
1
Nicaragua
1
San Marino
1
Guatemala
1
Peru
1
Chile
1
Taiwan
1
Sweden
1
Cuba
1
Costa Rica
1
Ecuador
1
Netherlands
1
South Africa
1
Colombia
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(10 years from now) | |
US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) | |
US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(10 years from now) |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults
Dosage: CAPSULE, DELAYED RELEASE;ORAL
10
United States
2
China
1
Spain
1
Hong Kong
1
Philippines
1
Denmark
1
Poland
1
Russia
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Japan
1
New Zealand
1
Croatia
1
Korea, Republic of
1
Israel
1
Chile
1
Portugal
1
Mexico
1
Australia
1
Slovenia
1
Hungary
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic